These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8934528)

  • 1. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas.
    Malkowicz SB; Tomaszewski JE; Linnenbach AJ; Cangiano TA; Maruta Y; McGarvey TW
    Oncogene; 1996 Nov; 13(9):1831-7. PubMed ID: 8934528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of p21WAF1/CIP1 in primary bladder tumors.
    Lacombe L; Orlow I; Silver D; Gerald WL; Fair WR; Reuter VE; Cordon-Cardo C
    Oncol Res; 1996; 8(10-11):409-14. PubMed ID: 9114433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
    Hermanová M; Lukás Z; Kroupová I; Kleibl Z; Novotný J; Nenutil R; Pazourková M; Brázdil J; Kren L; Díte P
    Neoplasma; 2003; 50(5):319-25. PubMed ID: 14628083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.
    Migaldi M; Sgambato A; Garagnani L; Ardito R; Ferrari P; De Gaetani C; Cittadini A; Trentini GP
    Clin Cancer Res; 2000 Aug; 6(8):3131-8. PubMed ID: 10955794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx.
    Nadal A; Jares P; Cazorla M; Fernández PL; Sanjuan X; Hernandez L; Pinyol M; Aldea M; Mallofré C; Muntané J; Traserra J; Campo E; Cardesa A
    J Pathol; 1997 Oct; 183(2):156-63. PubMed ID: 9390027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation.
    Lee CC; Yamamoto S; Wanibuchi H; Wada S; Sugimura K; Kishimoto T; Fukushima S
    Cancer Res; 1997 Nov; 57(21):4765-76. PubMed ID: 9354438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53-independent expression of p21waf1/cip1 in preinvasive and invasive squamous neoplasms of the uterine cervix.
    Werness BA; Wang HQ; Chance J; Goldstein DJ
    Mod Pathol; 1997 Jun; 10(6):578-84. PubMed ID: 9195575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpression.
    Kralj M; Husnjak K; Körbler T; Pavelić J
    Cancer Gene Ther; 2003 Jun; 10(6):457-67. PubMed ID: 12768191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations.
    Viale G; Pellegrini C; Mazzarol G; Maisonneuve P; Silverman ML; Bosari S
    J Pathol; 1999 Feb; 187(3):302-7. PubMed ID: 10398083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent association of p53 gene mutation in invasive bladder cancer.
    Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
    Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer.
    Ralhan R; Agarwal S; Mathur M; Wasylyk B; Srivastava A
    Clin Cancer Res; 2000 Jun; 6(6):2440-7. PubMed ID: 10873097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer.
    Bennett WP; el-Deiry WS; Rush WL; Guinee DG; Freedman AN; Caporaso NE; Welsh JA; Jones RT; Borkowski A; Travis WD; Fleming MV; Trastek V; Pairolero PC; Tazelaar HD; Midthun D; Jett JR; Liotta LA; Harris CC
    Clin Cancer Res; 1998 Jun; 4(6):1499-506. PubMed ID: 9626468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of the tumor suppressor gene p53 and WAF1 gene expression by IP6 in HT-29 human colon carcinoma cell line.
    Saied IT; Shamsuddin AM
    Anticancer Res; 1998; 18(3A):1479-84. PubMed ID: 9673359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity.
    Yasui W; Akama Y; Kuniyasu H; Yokozaki H; Semba S; Shimamoto F; Tahara E
    J Pathol; 1996 Oct; 180(2):122-8. PubMed ID: 8976868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p21WAF1/CIP1 gene DNA sequencing and its expression in human osteosarcoma.
    Liao WM; Zhang CL; Li FB; Zeng BF; Zeng YX
    Chin Med J (Engl); 2004 Jun; 117(6):936-40. PubMed ID: 15198903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations.
    Ozçelik H; Mousses S; Andrulis IL
    Clin Cancer Res; 1995 Aug; 1(8):907-12. PubMed ID: 9816061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers.
    Sinicrope FA; Roddey G; Lemoine M; Ruan S; Stephens LC; Frazier ML; Shen Y; Zhang W
    Clin Cancer Res; 1998 May; 4(5):1251-61. PubMed ID: 9607584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.